SLC22A1抗体

+ +

•  

   

     Flow cytometric analysis of Jurkat cells using SLC22A1 mouse mAb (green) and negative control (purple).    

  
  

The SLC22A1 antibody is a crucial tool for studying the organic cation transporter 1 (OCT1), encoded by the SLC22A1 gene. OCT1 is a polyspecific transmembrane protein primarily expressed in the liver, where it facilitates the uptake of endogenous compounds (e.g., neurotransmitters, carnitine) and xenobiotics (e.g., metformin, cisplatin) into cells. It belongs to the solute carrier family 22 (SLC22), which plays a vital role in drug absorption, distribution, and excretion. Researchers use SLC22A1 antibodies to investigate OCT1’s expression patterns, subcellular localization, and functional regulation in physiological and pathological contexts, such as metabolic diseases, cancer, and drug resistance.

Altered OCT1 activity due to genetic polymorphisms or dysregulated expression is linked to interindividual variability in drug responses and toxicity. For example, reduced OCT1 function impacts the pharmacokinetics of metformin, a first-line antidiabetic drug. The antibody aids in identifying OCT1-deficient patients who may require adjusted dosages. It is widely employed in techniques like Western blotting, immunohistochemistry, and flow cytometry to assess protein levels in tissues or cell lines.

Recent studies also explore OCT1’s role in cancer progression, as its expression in tumors may influence chemotherapeutic efficacy. Validating SLC22A1 antibody specificity through knockout controls is critical to avoid cross-reactivity with related transporters (e.g., OCT2/OCT3). Overall, this antibody supports advances in pharmacology, toxicology, and personalized medicine.